StockTipsArenaBeta

BUY Marksans Pharma Limited — Anshul Jain, Lakshmishree Investment and Securities

BUYMarksans Pharma Limited

byAnshul Jain, Lakshmishree Investment and SecuritiesHorizon: NA (inferred Swing (≤2wk))20 May 2026via Business Today

Entry₹210Stated
Target₹245
Total upside +16.67% (call closed)
Stop lossNot given
Exit—No position was opened
ExpiredNA
Follow Anshul Jain for new calls(32% target hit, 31 closed calls)Get alertsWatch MARKSANS for new buy/sell callsGet alertsSee 264 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 6 Sept, 11:22 pm IST
2 supporting1 neutral0 opposing
Supports the BUY call (2)

Marksans Pharma Limited is acquiring 100% of Netherlands-based QliniQ B.V., expanding its presence in European markets.

NSE · Press Release·1 Jun · 2d ago

(opens in new tab)

Marksans Pharma Limited achieved historic triple: highest Revenue, EBITDA & PAT, delivering on its ₹3,000 Cr Net Income guidance.

NSE · Press Release·26 May · 1w ago

(opens in new tab)
Neutral / worth noting (1)

Marksans Pharma Limited announced its audited financial results for the quarter and year ended March 31, 2026. The company also recommended a final dividend of Rs. 0.90 per equity share.

NSE · Outcome of Board Meeting·26 May · 1w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.